Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Faron Pharmaceuticals (FARN) Share Price

Price 44.50p on 31-03-2026 at 18:50:06
Change 0.50p 1.14%
Buy 46.00p
Sell 43.00p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 25,000.00 at 44.25p
Day's Volume: 124,488
Last Close: 44.50p
Open: 44.00p
ISIN: FI4000153309
Day's Range 44.00p - 44.50p
52wk Range: 42.50p - 265.00p
Market Capitalisation: £56.02m
VWAP: 44.56793p
Shares in Issue: 125.89m

Sector: Medicine and Biotech

Listed In: FTSE AIM 100, FTSE AIM All-Share,

Faron Pharmaceuticals (FARN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 25,000 44.25p Ordinary
 16:39:50 - 31-Mar-26
Buy* 1,991 44.94999p Ordinary
 15:38:17 - 31-Mar-26
Buy* 10,998 44.95p Ordinary
 15:14:14 - 31-Mar-26
Buy* 4,355 44.7777p Ordinary
 14:55:16 - 31-Mar-26
Buy* 4,254 44.7777p Ordinary
 14:09:16 - 31-Mar-26
Buy* 147 46.00p Ordinary
 13:34:33 - 31-Mar-26
Buy* 2,000 45.00p Ordinary
 13:34:07 - 31-Mar-26
Buy* 3,800 45.00p Ordinary
 12:57:45 - 31-Mar-26
Sell* 1,172 43.55p Ordinary
 12:38:45 - 31-Mar-26
Sell* 20,000 43.55p Ordinary
 12:38:23 - 31-Mar-26
See more Faron Pharmaceuticals trades

Faron Pharmaceuticals (FARN) Share Price History

Time period:
to
Date Open High Low Close Volume
30th Mar 2026 (Mon) 43.50 44.00 43.50 44.00 113,906
27th Mar 2026 (Fri) 43.50 43.50 43.50 43.50 47,565
26th Mar 2026 (Thu) 42.50 43.50 42.50 43.50 40,937
25th Mar 2026 (Wed) 43.00 43.00 43.00 43.00 78,493
24th Mar 2026 (Tue) 43.00 43.00 43.00 43.00 40,829
23rd Mar 2026 (Mon) 44.50 44.50 42.50 43.00 147,543
20th Mar 2026 (Fri) 44.50 44.50 43.50 44.50 28,062
19th Mar 2026 (Thu) 44.50 44.50 44.50 44.50 114,305
18th Mar 2026 (Wed) 45.50 45.50 44.50 44.50 270,904
17th Mar 2026 (Tue) 44.00 45.50 43.50 45.50 94,889
16th Mar 2026 (Mon) 46.00 46.00 43.50 44.00 142,096
13th Mar 2026 (Fri) 46.00 46.00 45.40 45.40 62,092
12th Mar 2026 (Thu) 47.00 48.00 45.00 46.00 119,447
11th Mar 2026 (Wed) 53.50 53.50 46.50 47.00 190,372
10th Mar 2026 (Tue) 47.50 53.50 47.50 53.50 304,011
9th Mar 2026 (Mon) 53.50 53.50 51.00 51.00 6,697
6th Mar 2026 (Fri) 53.50 55.00 53.50 53.50 201,166
5th Mar 2026 (Thu) 62.60 62.60 51.00 53.50 157,505
4th Mar 2026 (Wed) 51.00 58.00 58.00 58.00 179,142
3rd Mar 2026 (Tue) 53.50 53.50 51.00 51.00 111,949
See more Faron Pharmaceuticals price history

Faron Pharmaceuticals (FARN) Regulatory News

Date Source Headline
30th Mar 2026 7:30 am RNS Suspension - Faron Pharmaceuticals Oy
26th Mar 2026 7:00 am MFN Faron Pharmaceuticals Ltd: Faron appoints new CTO to strengthen late-stage development activities
25th Mar 2026 8:00 am MFN Faron Pharmaceuticals Ltd: Director Dealing
24th Mar 2026 4:30 pm MFN FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
19th Mar 2026 7:10 am MFN Faron Pharmaceuticals Ltd: Director Dealing
19th Mar 2026 7:05 am MFN Faron Pharmaceuticals Ltd: Director Dealing
19th Mar 2026 7:00 am MFN Faron Pharmaceuticals Ltd: Director Dealing
12th Mar 2026 2:30 pm RNS FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
12th Mar 2026 2:30 pm MFN FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
11th Mar 2026 6:20 pm RNS The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus
See more Faron Pharmaceuticals regulatory news

Faron Pharmaceuticals (FARN) Share News

IN BRIEF: Faron Pharmaceuticals hires Heikki Jouttijarvi as CTO

27th Mar 2026 07:00

Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Hires Heikki Jouttijarvi as chief technical officer, saying he has decades of experience in biopharma manufacturing, supply chain management and commercial operations. Chief Executive Officer Juho Jalkanen says: "His wealth of experience with commercial operations, manufacturing and supply chain management with late-stage and approved drugs is incredibly valuable for us as we progress with bexmarilimab to the announced phase IIb trial in higher-risk myelodysplastic syndromes". Bexmarilimab is an investigational immunotherapy designed to overcome resistance to existing treatments, among others. Myelodysplastic syndromes are a type of blood cancer. Read More

UK shareholder meetings calendar - next 7 days

23rd Mar 2026 16:21

Read More

AIM WINNERS & LOSERS: Physiomics jumps after Mike Whitlow ups stake

11th Mar 2026 10:42

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More

Faron shares soar as commercial talks on pipeline cancer drug underway

4th Mar 2026 17:22

(Alliance News) - Faron Pharmaceuticals Ltd shares rose over 14% on Wednesday after the Turku, Finland-based biopharma's chief executive officer said the company is in "in-depth commercial discussions" in his comment on the full-year results. Read More

UK earnings, trading statements calendar - next 7 days

25th Feb 2026 11:34

Read More

See more Faron Pharmaceuticals news
FTSE 100 Latest
Value10,176.45
Change48.49

Login to your account

Forgot Password?

Not Registered